| Summary: | Malaria is a parasitic disease with the highest morbidity and mortality worldwide and antimalarial drug resistance has increased in last two decades. Chloroquine and artemisinin which were usedfor the treatment of malaria are also reported with resistances. Recently, some metallic compounds of ruthenium and iridium have been used as possible therapeutic agents against other parasites such as Leishmania and Trypanosoma cruzi. Organic and inorganic compounds of vanadium such as metavanadate, have been used lately because its therapeutic properties as antineoplastic and hypoglycemic agents. In this study we evaluated the genotoxicity and cytotoxicity of metavanadate per os and its working dose, as a previous step for the future use of metavanadate as anti-parasitic agent in a Plasmodium yoelii yoelii malarial lethal model. Our findings suggest that 10 mg/kg is a safe dose that decreases parasitemia and increases the survival of the Plasmodium yoelii yoelii infected mice with no evidence of genotoxicity, cytotoxicity with the dose selected.
|
|---|
